KPV

Clinical Summary

KPV is a synthetic tripeptide (Lys-Pro-Val) — the C-terminal fragment of α-MSH (alpha-melanocyte-stimulating hormone). Identified in the late 1980s by Lipton's NIH group as the minimal anti-inflammatory pharmacophore of α-MSH, it carries the cytokine-suppressive activity of the parent hormone without the receptor-binding requirements that cause pigmentation in α-MSH analogs like Melanotan-2 and afamelanotide.

Who benefits most (theoretical): Individuals with active inflammatory bowel disease — particularly ulcerative colitis — who have failed first-line therapy and are seeking adjunctive options under medical supervision. The mechanism is unusually well-suited to colonic inflammation: KPV is taken up by the PepT1 transporter, which is normally restricted to the small intestine but is upregulated on colonocytes during IBD flares. The net effect is disease-state-selective drug delivery to inflamed tissue.

The honest reality: Despite ~30 years of mechanistic and animal work, only one human randomized trial of any KPV variant has been published — and it tested the D-isomer K(D)PT, not free-base KPV (Kucharzik et al. 2017, Inflamm Bowel Dis, PMID: 28092306). That Phase IIa add-on trial in mild-to-moderate UC was well tolerated and showed efficacy signal after subgroup analysis but has not progressed to Phase III. There are zero registered KPV trials on ClinicalTrials.gov as of April 2026. There are zero FAERS reports for KPV in OpenFDA.

Why the gap: KPV is a 3-amino-acid sequence, unpatentable, and has no pharmaceutical sponsor. The original commercial program (Dr. August Wolff GmbH, K(D)PT) appears to have stalled after Phase IIa — sponsor never registered a follow-up trial.

Regulatory inflection point: In 2023, FDA placed KPV in Category 2 (insufficient safety data) on the bulk drug substance list, effectively prohibiting 503A and 503B compounding pharmacies from dispensing it. The Pharmacy Compounding Advisory Committee is scheduled to reconsider KPV on July 23–24, 2026 — a real decision point that could move it to Category 1 (compounding-allowed, similar to the BPC-157 precedent of February 2026), keep it Category 2, or reaffirm the prohibition. Until that meeting, all US KPV is from research-chemical vendors with the usual gray-market quality issues.

Differs from related α-MSH analogs: Unlike Melanotan-2 / afamelanotide, KPV does not bind melanocortin receptors (MC1R/MC3R/MC4R/MC5R). This is mechanistically confirmed across three independent studies (Getting 2003, Elliott 2004, Muceniece 2003). KPV does not cause pigmentation, does not raise cAMP, and the anti-inflammatory effect is preserved in MC1R-null (e/e) mice. The molecular target appears to be the importin-α nuclear import machinery, where KPV blocks NF-κB p65RelA translocation.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. AHE caps at 2/5. UCC caps at 3/5. ME caps at 2/5. FA caps at 1/5. NE caps at 1/5.

D-isomer caveat: The 3/5 rating for UC reflects the K(D)PT (Lys-D-Pro-Val) Phase IIa trial, NOT free-base KPV. Hiltz 1991 SAR work showed D-Pro12 substitution alters but does not abolish activity, and the D-isomer has improved proteolytic stability. Do not treat the K(D)PT result as direct evidence for free-base KPV products sold in research-chemical channels.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal | AVOID Contraindicated for this indication

Star rating legend: 5/5 Multiple large RCTs + meta-analyses | 4/5 Several human RCTs | 3/5 Some human pilot data | 2/5 Animal only or very limited human | 1/5 No evidence

Human Study Detail (the only one)

Kucharzik et al. (2017) — K(D)PT in mild-to-moderate UC (PMID: 28092306). Multicenter Phase IIa randomized, double-blind, placebo-controlled. Tested the D-isomer K(D)PT, not free-base KPV. Add-on to background 5-ASA / immunomodulator therapy. Primary endpoint: safety. Secondary: clinical response. Result: well tolerated, efficacy signal in subgroup analysis (high placebo response in primary analysis). Sponsor: Dr. August Wolff GmbH. No Phase III follow-up has been registered or published as of April 2026. This is the entire human evidence base for any KPV variant.

Prescribing

Strong caveat: All dosing below is documentary, not prescriptive. Free-base KPV has zero human PK data — no measured Tmax, half-life, distribution volume, or bioavailability in any species. The community-consensus oral dose was extrapolated from rodent IBD work without a human dose-finding study.

Dosing

Unit-confusion red flag: A "250 mg twice daily" figure circulates widely on AI-generated review sites. This is inconsistent with vial sizes (5–10 mg total per gray-market vial) and is almost certainly a mcg→mg unit error that has propagated across templated content. Real community dosing is microgram-scale.

Formulations

Route ranking: Oral 3/5 (PepT1 disease-targeted) > Topical 2/5 (skin) > SubQ 1/5 (no published human use case)

Safety

Interactions

Contraindications

Absolute:

• Active malignancy or history of cancer within 5 years — KPV's anti-inflammatory mechanism includes NF-κB suppression; NF-κB has dual roles in tumor biology, and KPV has not been studied in tumor-bearing organisms. Use of any unstudied anti-inflammatory in undiagnosed populations carries occult-cancer risk.
• Pregnancy and lactation — zero safety data; KPV has not been characterized in reproductive toxicology.
• Known hypersensitivity to peptide therapeutics.

Relative (use with extreme caution):

• Severe immunocompromise — anti-inflammatory layered on immunosuppression has unmeasured synergy.
• Active systemic infection — NF-κB suppression during infection is generally undesirable.
• Pediatric (<18) — zero data.
• Severe renal or hepatic impairment — no PK data; clearance route unknown.

Adverse Effects

Reported in the only human RCT (K(D)PT Phase IIa, N undisclosed in abstract): "Well tolerated." No specific AE breakdown published.

However: A single Phase IIa with a non-prescribed N at four-week follow-up is grossly insufficient to characterize safety. Many real drug AEs require N>1,000 or year-plus exposure to surface.

Community-reported side effects (anecdotal, ~100–200 self-reports):

• Mild GI upset / nausea — uncommon (~3–5% of oral users)
• Injection-site reactions — uncommon (~8–12% of injectors); resolves within 12–48 hours
• Orange skin staining from topical formulations — multiple reports; cosmetic only, washes off in days
• "No effect" — recurrent minority across all routes
• Mood / sleep / anxiety / hair / cognitive effects — essentially absent in community reports (a notable contrast with the much louder community signal around BPC-157)

Theoretical concerns:

• NF-κB suppression in undetected malignancy — KPV blocks p65RelA nuclear translocation; NF-κB pathways are dysregulated in many tumors, and the safety implications of generic NF-κB suppression in unscreened populations are not characterized.
• Immunogenicity — peptide therapeutics can elicit antibody responses with prolonged exposure; not measured for KPV.
• Sourcing variability — gray-market vials lack HPLC purity verification; 503A compounding pharmacies have been blocked since 2023.

FAERS Signal Table (from BioMCP)

Reading FAERS data: Absence of signal is not evidence of safety. KPV exposure is invisible to FAERS because there is no approved KPV product to be reported on. Any safety conclusions must come from the K(D)PT Phase IIa data and small community report base, both of which are dramatically underpowered.

Monitoring

Stop immediately if: new pain, fever, signs of infection, unexpected systemic symptoms, lab abnormalities, or no improvement by 4–6 weeks.

Special Populations

Renal Impairment

Hepatic Impairment

Note: No human PK data exists for any KPV formulation. All special-population guidance is precautionary, not evidence-based.

Synergies & Stacking

Common community stacks:

• BPC-157 + KPV — the dominant pairing, especially for IBD and MCAS users
• KLOW blend (KPV + BPC-157 + GHK-Cu + TB-500) — pre-mixed gray-market vial sold as the anti-inflammatory analog to GLOW (cosmetic-only blend)
• KPV + LL-37 — niche MCAS / chronic-infection stack, low volume

Individual Response Modifiers

Sex-Specific Considerations

No clinically significant compound-specific sex differences are documented for KPV. The above reflects gaps and population-base differences, not pharmacological differences.

Genetic Modifiers

No other compound-specific pharmacogenomic modifiers are documented. The α-MSH receptor variants (MC1R rs1805007 / rs1805008 etc.) do not apply to KPV — KPV does not bind melanocortin receptors.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-leaning-positive across approximately 100–200 identifiable reports. Discussion volume is roughly 1/20th of BPC-157. r/Peptides has hundreds of mentions but only ~20–30 dedicated KPV threads. Polarization tracks indication: gut, skin, and MCAS users skew net-positive; recreational biohacker users frequently report "no effect."

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: None identified. KPV is not in the Limitless Life / Pinnacle / Tailor Made retail-MLM peptide rotation that surrounds GLP-1s.
• Influencer concentration: Hype is not driven by a single named influencer (notable contrast with BPC-157). Derek (More Plates More Dates), Ben Greenfield, Huberman — none have a flagship KPV episode. The most-cited single source is the Diary of Recovery blog (one author's MCAS recovery narrative), which propagates into clinic marketing copy.
• Astroturfing / vendor seeding: Highly likely on Tier-2 sources. Most Google-indexed "KPV reviews" are clinic blogs and vendor sites with affiliate or service-sale incentive. Reddit r/Peptides is much more measured than the clinic-blog corpus.
• Commercial bias: Strong. Positive write-ups correlate near-100% with either (a) vendor selling KPV vials, or (b) a clinic offering KPV peptide therapy.
• AI deepfake / fake-celebrity endorsement: None documented for KPV specifically — too obscure for that scam vector.
• AI-generated content slop: Heavy. The recurring "250 mg twice daily" unit error is a fingerprint of cross-site AI scraping.

Folk vs Clinical Reality Check

Community gut-healing reports align cleanly with the preclinical literature — KPV is actively transported by PepT1 into inflamed colonic epithelium and inhibits NF-κB at low concentrations (Dalmasso 2008, Kannengiesser 2008 mouse colitis models). Topical anti-inflammatory effects in atopic dermatitis match the α-MSH C-terminus mechanism. Community experience diverges sharply from the literature on (1) MCAS / histamine / mast-cell stabilization — not in any KPV-specific PubMed paper despite being a near-universal clinic-blog talking point, (2) systemic anti-aging / longevity claims — no preclinical support, and (3) the high-dose ("1–1.5 mg/day") clinic protocols, which exceed community consensus and have no PK rationale. The most likely explanations for divergence: placebo + regression-to-mean in self-selecting MCAS populations, co-intervention bias (most users are simultaneously on BPC-157 + low-histamine diet + supplements), sourcing variability (gray-market vial purity unknown), and AI-template content propagating dose claims that no human study supports.

Deep Dive: Mechanisms & Research

Key Mechanisms (With Clinical Translation)

1. PepT1-mediated colon-selective uptake. PepT1 (SLC15A1) is normally restricted to the small intestine but is upregulated on colonocytes during IBD flares. KPV is a PepT1 substrate and is selectively imported into inflamed colonic tissue. PepT1-knockout mice do not respond to oral KPV (Viennois 2016, PMID: 27458604), confirming the transporter as the obligate uptake route. Clinical translation: This is the strongest "drug-likeness" story for KPV — it is naturally disease-state-selective for the indication with the most preclinical support (UC). Whether human PepT1 expression matches mouse colitis models is unverified.

2. NF-κB importin-α/p65RelA blockade. Land 2012 (PMID: 22837805) showed KPV enters the nucleus and competes for the Imp-α3 binding site on p65RelA, blocking nuclear translocation and stabilizing IκBα. Clinical translation: This is the most molecularly resolved anti-inflammatory mechanism for KPV. It explains the cytokine suppression observed across multiple cell types and the consistency of the anti-inflammatory effect direction.

3. IL-1β functional antagonism. KPV (and especially the D-Pro variant K(D)PT — distinct from the IL-1β(193-195) peptide K(D)PT but often conflated) shows sequence overlap with IL-1β(193-195) and behaves as a functional IL-1β antagonist (Haddad 2001, PMID: 11256945; Getting 2003, PMID: 12750433). Clinical translation: Adds a parallel mechanism to NF-κB blockade — both converge on cytokine suppression.

4. Cytokine suppression downstream. Reproducible across keratinocyte, bronchial epithelial, intestinal epithelial, and macrophage models: ↓TNF-α, ↓IL-1β, ↓IL-6, ↓IL-8/eotaxin, ↓iNOS/NO, ↓MPO, ↓MMP-9 (multiple PMIDs). Clinical translation: The cytokine effect is robust and reproducible in animal models. Translation to human disease endpoints (clinical remission, mucosal healing) remains untested.

5. Anti-pyroptotic / anti-apoptotic. KPV blocks ROS-mediated caspase-1 activation and cleaved caspase-3 in PM₁₀-stressed keratinocytes (Sung 2025, PMID: 40073467); reduces apoptosis post-TBI (Schaible 2013, PMID: 23940690). Clinical translation: Emerging mechanism, single-paper evidence per indication.

6. NOT melanocortin receptor-dependent. Three independent papers (Getting 2003, Elliott 2004, Muceniece 2003) confirm KPV does not bind MC1R/MC3R/MC4R/MC5R, does not raise cAMP, and the anti-inflammatory effect is preserved in MC1R-null (e/e) mice. Clinical translation: This is what differentiates KPV from Melanotan-2 and afamelanotide — no pigmentation, no melanocyte-dependent off-targets, but also no benefit from MCR-mediated effects (mood, appetite, sexual function) reported with MCR agonists.

7. Mast cell stabilization (claimed, NOT supported in KPV-specific literature). This is repeated across functional-medicine and clinic blogs but has no KPV-specific PubMed paper. The mast-cell angle belongs to broader α-MSH literature; KPV does not signal through MCRs that mediate mast-cell modulation. Treat as folk claim, not mechanism.

Pharmacokinetics (Critical Gap)

• Half-life: not characterized in humans
• Tmax, Cmax, distribution volume, protein binding: ALL UNKNOWN
• Metabolism: presumed peptidase-mediated; no formal study in humans
• Oral bioavailability: never measured in any species; PepT1-mediated uptake is the proposed disease-selective route
• Topical permeation: limited data — Pawar 2017 (PMID: 28343991) characterized iontophoretic delivery; passive permeation is small but non-zero
• No formal ADME study has ever been published in humans.

Research Concentration Warning

Free-base KPV's published evidence base is dominated by two clusters:

• The Lipton / Catania / Hiltz NIH lineage (1980s–1990s foundational anti-inflammatory work)
• The Wenzhou Medical University and adjacent groups (2010s–2020s preclinical IBD delivery-system papers; multiple hydrogel and nanoparticle formulations)

The single human RCT was sponsored by Dr. August Wolff GmbH (German specialty pharma) and tested the D-isomer K(D)PT, not free-base KPV. Wolff has not registered a follow-up trial.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

No registered trials for free-base KPV under any name on ClinicalTrials.gov, JPRN, CRiS, ChiCTR, or Taiwan registry as of April 2026. The single human RCT (K(D)PT, PMID 28092306) was not registered with an NCT ID — likely registered under a EudraCT identifier that is not indexed by BioMCP.

Regulatory Status

• FDA: Not approved. Category 2 bulk drug substance since 2023 — insufficient safety data; 503A and 503B compounding pharmacies are prohibited from compounding KPV. Pharmacy Compounding Advisory Committee reconsideration scheduled 2026-07-23/24 — possible reclassification to Category 1 (compounding-allowed), continuation of Category 2, or affirmation of prohibition.
• EMA: Not approved. No marketing authorization filed in EU or UK.
• TGA (Australia): No specific TGA monograph; defaults to Schedule 4 (prescription only) under the 2023 "synthetic peptides not in approved products" rule.
• WADA: Not specifically named on the prohibited list. The S0 catch-all for non-approved substances applies — competitive athletes should treat as risky.
• NCAA: No specific listing; same S0-style risk.
• Regulatory context: KPV is a 3-amino-acid sequence, unpatentable, with no pharmaceutical sponsor since the Wolff K(D)PT program stalled. The 2023 FDA Category 2 placement was made on safety-data grounds, not efficacy-data grounds. The July 2026 PCAC reconsideration is the genuine inflection point — a Category 1 ruling would legitimize compounding-pharmacy supply (similar to the BPC-157 February 2026 reclassification).

Ataraxia Verdict (as of 2026-04-29)

Hype Check (Mode 1: Fallacy Radar)

Overblown claims:

• "KPV stabilizes mast cells" — propagated in functional-medicine and clinic content; not supported in KPV-specific PubMed literature. The mast-cell angle belongs to broader α-MSH research.
• "KPV is the safest peptide" — absence of FAERS reports reflects absence of approval and exposure tracking, not characterized safety. The longest-followed exposed cohort is four weeks (K(D)PT Phase IIa).
• "Modern protocols use 1–1.5 mg/day" — no human dose-finding study supports this. Likely a propagated unit-error fingerprint from AI-generated review sites (250 mg → mcg conversion error).
• "Anti-aging / longevity" — zero mechanistic or clinical support.

Fallacies detected:

• Hasty generalization (HIGH): rodent IBD studies → "works in human gut conditions broadly." Translation rate for anti-inflammatory peptides is historically <10%.
• Appeal to absence (HIGH): "no FAERS reports" used as a safety claim. KPV is invisible to FAERS.
• Cherry-picking (MEDIUM): the Cutuli 2000 antimicrobial paper is widely cited; the Songok 2018 negative replication is rarely mentioned.
• Sister-peptide conflation (HIGH): K(D)PT IL-1β(193-195) results are conflated with K(D)PT (Lys-D-Pro-Val) results, even though they are distinct molecules. The Wolff Phase IIa trial used Lys-D-Pro-Val, not the IL-1β fragment.

Legitimately supported (in animals + 1 small human trial):

• Anti-inflammatory cytokine suppression in colitis models — consistent across multiple independent groups.
• PepT1-mediated colon-selective uptake — molecularly characterized.
• NF-κB importin-α blockade — molecularly resolved.
• Phase IIa UC tolerability for the D-isomer K(D)PT.

Evidence Classification (Mode 5: Evidence Classifier)

Synthesized view in Indications & Evidence table above (Type + BH + Safety columns). Detailed rationale below.

Evidence Gaps

• No human pharmacokinetic data — no Tmax, half-life, distribution volume, oral bioavailability for any KPV formulation in any human population.
• No completed Phase III — the single human RCT was Phase IIa for K(D)PT (D-isomer) and had no follow-up.
• No long-term safety data — longest exposure is four weeks.
• No free-base KPV human trial — every "use" is extrapolated from rodent data and the K(D)PT Phase IIa.
• No reproductive safety data — pregnancy, lactation, fertility all unstudied.
• No tumor-bearing safety data — KPV's NF-κB suppression has not been studied in cancer-bearing organisms.
• PepT1 expression in human IBD vs mouse models — mechanistic basis is mouse-derived; not directly verified in humans.
• D-isomer vs L-isomer translation — the only positive human trial was for the D-isomer; SAR work shows L-Pro is essential for activity, but K(D)PT clinical signal cannot be assumed to apply to free-base KPV gray-market product.

Bias Flags (Mode 4: First Principles)

• Single-trial bias: the entire human evidence base is one Phase IIa from one sponsor (Wolff) for one variant (K(D)PT) in one indication (UC). Treating this as "KPV works in humans" is a category error.
• Sister-peptide bias: K(D)PT (Lys-D-Pro-Val) and K(D)PT (IL-1β fragment Lys-D-Pro-Thr) are distinct molecules but commonly conflated in citations and clinic content.
• Publication bias: the preclinical IBD literature is uniformly positive — no large-scale negative-results database. With a fully unblinded animal-model field, 100% positive results raise the same flags they do for BPC-157.
• Sponsor abandonment is itself a signal: Wolff completed Phase IIa in 2017 and has not registered Phase III. Reasons could be commercial (unpatentable peptide, weak commercial viability) or scientific (efficacy signal not strong enough to justify Phase III). Both are plausible. Either way, the absence is informative.
• AI-content slop: the dominant Google search results for "KPV peptide" are templated AI-generated review pages with vendor affiliate incentive. The "1–1.5 mg/day" dose claim and "250 mg twice daily" unit error are fingerprints.
• MCAS niche capture: a small, motivated MCAS / functional-medicine community has elevated KPV's profile beyond what its evidence base supports. The "Diary of Recovery" blog is the single most-influential narrative source.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Lower-key than BPC-157 but present. Vendor-driven SEO is the dominant content layer; clinic-blog content correlates near-100% with affiliate or service-sale incentive. AI-templated content has propagated specific dose errors.
• Influencer economics: Notably absent at the major-influencer level. No Huberman / Greenfield / Rogan flagship episode on KPV. The community is bottom-up rather than top-down.
• Counter-narrative manipulation: The 2023 FDA Category 2 placement is real but its framing varies — vendor sites characterize it as "FDA overreach"; mainstream coverage treats it as evidence-gap-driven. Both readings have merit; cui bono on each side is non-trivial.
• Cui bono summary: Pro-KPV: 503A/503B compounding pharmacies (loss of revenue from 2023 ban; would benefit from Category 1 reclassification), peptide vendors (active gray-market sales), clinic operators offering peptide therapy as service, MCAS patient communities. Anti-KPV: pharmaceutical anti-inflammatory competitors (5-ASA, biologics, JAK inhibitors), regulators justifying enforcement budgets. Neither side is disinterested.
• Red team highlight (most concerning angle): the propagation of "1.5 mg/day" oral protocols. This dose mirrors the K(D)PT Phase IIa dose (1.5 mg t.i.d.) but applies it to free-base KPV oral capsules without acknowledging the D-isomer was a different molecule with different proteolytic stability. The community is taking a 4.5 mg/day Phase IIa-validated D-isomer dose and rebranding it as a 1.5 mg/day free-base regimen — neither of which has a free-base human trial behind it.

Decision Support (Mode 3: Clarity Compass)

• Evidence strength: Low–moderate preclinical (multiple independent rodent groups for IBD, mechanistic resolution at the importin-α level), weak–null clinical (one Phase IIa for D-isomer K(D)PT). Strong mechanistic story, very thin clinical validation.
• Health utility score: 4/10 — the disease-state-selective PepT1 mechanism is genuinely interesting and IBD evidence breadth is real, but the absence of free-base human data and the single-trial human evidence base cap utility at "promising research compound, not a validated therapy."
• Opportunity cost: ~$50–150/month for oral protocols, $80–200/month for compounded topical, $40–100/month for SubQ vials. Daily oral or topical application is a moderate compliance burden. Risk budget is consumed on an unproven compound that is currently regulatory-prohibited from compounding pharmacies.
• Hell Yes or No (Sivers): No. The evidence isn't strong enough for an enthusiastic yes, and the regulatory uncertainty is unresolved until July 2026.
• Regret minimization (5 years): Limited regret either way unless you have refractory IBD that fails first-line therapy and you have specialist supervision.
• Verdict: CONDITIONAL.
• Conditions: (1) Active UC or other IBD flare that has failed 5-ASA + immunomodulator + (where indicated) biologics under specialist care. (2) Source from a 503A-accredited compounding pharmacy IF KPV is reclassified to Category 1 at the July 2026 PCAC meeting; otherwise no compliant supply path exists. (3) Medical supervision with baseline labs and inflammation markers. (4) Time-limited 4–6 week trial with clear stop criteria. (5) No active malignancy or recent cancer history. (6) Not pregnant, lactating, or planning pregnancy.
• If conditions not met: WATCH LIST. Re-evaluate after the July 23–24, 2026 PCAC ruling and any follow-up Phase III data on K(D)PT.

Bottom Line

KPV is a mechanistically well-characterized anti-inflammatory tripeptide whose evidence base is dominated by preclinical rodent IBD work, a molecularly resolved NF-κB importin-α blockade story, and a single positive Phase IIa human trial — but for the D-isomer K(D)PT, not free-base KPV. The disease-state-selective PepT1 uptake is genuinely interesting and the mechanism translation is more rigorous than most gray-market peptides. However, every clinical use of free-base KPV currently sits on rodent extrapolation plus one D-isomer trial that has not progressed to Phase III seven years later. The community signal is much smaller than BPC-157 and notably free of celebrity-driven hype, but the AI-content layer has propagated a specific dose error worth flagging. The July 2026 PCAC reconsideration is the real near-term inflection point — it will determine whether 503A pharmacies can dispense KPV or whether the 2023 prohibition stands. Until then, free-base KPV is research-chemical-only, with the usual gray-market quality concerns and no compliant US supply path.

Practical Notes

Brands & Product Selection

Post-2023 landscape: FDA Category 2 placement effectively prohibited 503A and 503B compounding pharmacies from dispensing KPV. The compliant US supply path is currently closed pending the July 23–24, 2026 PCAC reconsideration. Free-base KPV is therefore sold exclusively through "research-use-only" peptide vendors, with no FDA-regulated quality assurance.

Quality markers (gray-market sourcing — not endorsed): Certificate of Analysis with HPLC purity ≥98%, mass spectrometry confirmation of the Lys-Pro-Val sequence, endotoxin <0.5 EU/mL. Refuse any product without batch-specific CoA. Oral KPV capsules on Amazon are particularly suspect; some have been documented as amino-acid blends without the actual tripeptide.

Vendors observed in community channels: Peptide Sciences, Limitless Life, Pure Peptides, Simple Peptide, Alpha Omega, BioLongevity Labs, BiogenicFoods, MyBodyTonic (capsules). Pre-mixed KLOW blend (KPV + BPC-157 + GHK-Cu + TB-500) is available from several of these. No endorsement implied — listed for documentary purposes only.

Storage & Handling

• Lyophilized (unreconstituted): Freezer (-20°C) up to 2 years; fridge (2–8°C) 3–6 months. Protect from moisture.
• Reconstituted: Fridge only, 30 days max. Discard if cloudy or particulate.
• Reconstitution: Add bacteriostatic water slowly down vial side. Swirl gently — never shake. Typical concentration 1–2 mg/mL for a 5 mg or 10 mg vial.
• Topical compounded creams: Refrigerate; shelf life 30–90 days depending on formulation.
• Oral capsules: Cool dry storage; check expiration on the bottle.

Palatability & Compliance

Oral capsule: No taste issue; standard compliance (one or two capsules per day). The dominant route in community use.

Topical cream: May produce orange staining on light skin and clothing — washes off in days. Patch-test for irritation before broader application.

SubQ injection: Daily SubQ over 4–6 weeks is a moderate compliance barrier. Insulin syringe (29–31 gauge), rotate sites.

Reference Ranges (Expected Biomarker Changes)

No documented biomarker changes from human RCTs exist for free-base KPV. The K(D)PT Phase IIa primary endpoint was safety; secondary efficacy endpoints did not include systematically reported biomarker shifts. Monitoring is therefore for safety surveillance and indication-specific clinical response (e.g. UC symptom score, fecal calprotectin if available), not for KPV-specific biomarker tracking.

Cost

Total monthly cost estimate: $30–150 depending on route, dose, and source.

What We Don't Know

• Whether the K(D)PT Phase IIa UC signal would replicate for free-base KPV in a properly powered Phase III.
• Optimal human dose for any indication.
• Human pharmacokinetics — Tmax, half-life, oral bioavailability, distribution.
• Whether oral KPV is bioavailable in non-IBD populations (PepT1 expression on healthy colonocytes is low).
• Long-term safety beyond the four-week K(D)PT exposure window.
• Whether KPV affects tumor biology in cancer-bearing organisms.
• Whether the community-reported MCAS / histamine effects are real, placebo-mediated, or attributable to co-interventions.
• Why Dr. August Wolff GmbH did not progress K(D)PT to Phase III.
• The outcome of the July 23–24, 2026 PCAC reconsideration meeting.
• Whether KPV interacts meaningfully with biologic therapies for IBD (TNF inhibitors, anti-integrins, JAK inhibitors).
• Topical KPV permeation kinetics in inflamed vs. healthy skin.
• Whether any KPV stereoisomer or analog is in active commercial development as of 2026.

References

Human Trials

• Kucharzik T et al. (2017). Modulation of intestinal inflammation by the cutaneous melanocortin pathway: effects of K(D)PT in mild-to-moderate UC. Inflamm Bowel Dis. PMID: 28092306. Phase IIa, multicenter, RCT. D-isomer; only human KPV-variant trial.

Mechanism — IBD / Gut

• Dalmasso G et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PMID: 18061177.
• Kannengiesser K et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine IBD models. Inflamm Bowel Dis. PMID: 18092346.
• Viennois E et al. (2016). Critical role of PepT1 in colitis-associated cancer; therapeutic benefits of PepT1-mediated KPV. Mol Cancer Ther. PMID: 27458604.
• Laroui H et al. (2010). Drug-loaded PLA nanoparticles in polysaccharide hydrogel — KPV-NPs at ~12,000-fold lower dose than free KPV. Gastroenterology. PMID: 19909746.

Mechanism — Receptor and Signaling

• Getting SJ, Schiöth HB, Perretti M (2003). Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) — non-MCR mechanism. J Pharmacol Exp Ther. PMID: 12750433.
• Land SC (2012). KPV inhibits NF-κB by direct importin-α binding to p65RelA. Int J Physiol Pathophysiol Pharmacol. PMID: 22837805.
• Haddad JJ (2001). Lys-d-Pro-Val suppresses LPS-induced NF-κB; identified as IL-1β(193-195) antagonist. Biochem J. PMID: 11256945.
• Elliott RJ et al. (2004). KPV in HaCaT and normal keratinocytes — non-cAMP, transient Ca²⁺ flux only. J Invest Dermatol. PMID: 15102092.
• Hiltz ME, Catania A, Lipton JM (1991). KPV stereochemistry SAR — D-Lys11 retains activity, D-Pro12 abolishes it (L-Pro essential), D-Val13 ~4× more active. Peptides. PMID: 1788140.
• Muceniece R et al. (2003). MSH(11-13) C-terminal analogues inhibit NO production — non-MCR receptive site. Eur J Pharmacol. PMID: 12895656.

Mechanism — Other

• Sung J (2025). KPV mitigates fine dust (PM₁₀)-induced HaCaT keratinocyte apoptosis + inflammation; suppresses caspase-1 and IL-1β. Tissue Cell. PMID: 40073467.
• Bonfiglio V et al. (2006). Topical KPV accelerates corneal epithelial wound healing in rabbits; NO-dependent. Exp Eye Res. PMID: 16965771.
• Schaible EV et al. (2013). Single IP α-MSH(11-13) post-controlled cortical impact in mice → smaller secondary lesion. PLoS One. PMID: 23940690.

Mechanism — Foundational

• Hiltz ME, Lipton JM (1990). α-MSH(11-13) inhibits acute paw edema and contact sensitivity in mice. Peptides. PMID: 2284205.
• Richards DB, Lipton JM (1984). KPV antipyresis in rabbit. Peptides. PMID: 6333677.

Reviews

• Brzoska T et al. (2008). α-MSH and tripeptides KPV/K(D)PT review. Endocr Rev. PMID: 18612139. Comprehensive secondary source.
• Luger TA, Brzoska T (2007). α-MSH related peptides as anti-inflammatory drugs. Ann Rheum Dis. PMID: 17934097.
• Gravina AG et al. (2023). The melanocortin system in inflammatory bowel diseases. Cells. PMID: 37508552.
• Böhm M, Luger T (2019). Melanocortin peptides for cutaneous wound healing — KPV + KdPT. J Invest Dermatol. PMID: 30661264.
• Brzoska T et al. (2010). α-MSH-related peptides anti-inflammatory effects beyond pharmacophore. Adv Exp Med Biol. PMID: 21222263.

Antimicrobial — Conflicted

• Cutuli M et al. (2000). α-MSH peptides incl. KPV with antimicrobial effect vs S. aureus and C. albicans. J Leukoc Biol. PMID: 10670585.
• Songok AC et al. (2018). Glycoalkylated KPV analogs — no antimicrobial activity for KPV or analogs. PLoS One. PMID: 29953505.

Formulation / Delivery

• Pawar K et al. (2017). Transdermal iontophoretic KPV across microporated human skin. J Pharm Sci. PMID: 28343991.
• Pawar KR et al. (2015). Stability-indicating HPLC for KPV. J Pharm Biomed Anal. PMID: 25298219.
• Xiao B et al. (2017). HA-functionalized nanoparticles + chitosan/alginate hydrogel for oral colon-targeted KPV. Mol Ther. PMID: 28143741.

Regulatory & Trials

• FDA: Category 2 bulk drug substance since 2023. Pharmacy Compounding Advisory Committee meeting scheduled 2026-07-23/24 for KPV reconsideration.
• EMA: Not approved.
• TGA (Australia): Schedule 4 by default under 2023 synthetic-peptide rule.
• WADA: Not specifically named; S0 catch-all applies.
• ClinicalTrials.gov: 0 KPV-specific registered trials as of April 2026.